Public Health and Research News

NEW YORK, NY–(Marketwire – July 26, 2010) –  Every two years, healthcare market research firm Kalorama Information releases the highly anticipated update to its industry leading report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” In seven best-selling editions, Kalorama Information’s lead diagnostic analyst Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing, in one complete volume.

“We’re very pleased to release this completely updated edition of our best-selling title,” said Bruce Carlson, publisher of Kalorama Information. “The idea behind our unique report is that the entire market can be captured in one volume and business planners can use it as a key reference.”

This go-to reference for the IVD industry reveals the trends that are impacting the field now, and provides a realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. All of the major segments of clinical lab testing are covered.

Kalorama has reorganized the presentation of the IVD market in this latest edition in a manner that better reflects how the industry has evolved. For instance, there is an increased focus on lab automation. Due to a lack of trained lab technologists to run the more complex new set of molecular and histological tests and immunoassays, a proliferation of test and lab automation tools has been launched that remove precious human resources from mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones.

“Worldwide Market for In Vitro Diagnostic Tests, 7th Edition” stands as a testament to the Kalorama methodology — real industry knowledge combined with numerous interviews of leading experts in the field and company executives, as well as an exhaustive review of the medical, business, and company literature. More than 900 pages and over 230 key company profiles reveal one vital piece of exclusive industry information after another. The report is available at: http://www.kaloramainformation.com/redirect.asp?progid=79375&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

SILVER SPRING, MD–(Marketwire – July 20, 2010) – A critically needed modular laboratory facility is en route to Port-au-Prince thanks to a collaboration between the Association of Public Health Laboratories (APHL) and International Relief Solutions, LLC (IRS). The APHL Haiti Field Laboratory Support Team provided technical assistance to International Relief Solutions, LLC (IRS) in planning and design of the new laboratory, which will replace the temporary tent facility that has served the nation’s largest hospital since the January earthquake. 

The 24′ by 36′ modular laboratory will be erected at L’Hôpital de l’Université d’État d’Haïti (HUEH). Since the earthquake, the number of patients being treated at HUEH has tripled from 14,000 per month to almost 42,000 thus increasing demands for laboratory testing. Due to extremely high temperatures and no air conditioning in the tent, automated testing requiring cooler temperatures, such as hematology and blood chemistry, are being run manually. The result is that the current testing capacity is only 25% of the daily demand. The modular lab facility is designed with infrastructure for work benches, heating, ventilation, plumbing and electrical services. With direct hookup to electrical and water supplies, the laboratory building will have the air conditioning necessary to meet the requirements of the many intricate and delicate tests that the laboratory technicians on scene perform routinely. The lab will arrive with the electrical system and plumbing pre-installed allowing for a quick start-to-finish set up of approximately four days.

APHL Senior Technical Consultant and Team Leader for the APHL Haiti Field Laboratory Support Team, Dave Doherty, coordinated this effort from start to finish. Following the earthquake, the Centers for Disease Control and Prevention requested and authorized Doherty and his team to assist all of the public health network laboratories in Haiti in getting testing services back up and running to support the enormous demands for medical care and treatment. 

Better lab facilities will improve testing services and also enable laboratory technologists to get back to work. According to Doherty, “Many well-trained technologists in Haiti are unable to work and provide testing services because of the loss of laboratory facilities to earthquake damage.”

It could be years before the permanent structures are rebuilt; the new modular lab serves as a long term solution. This initiative was a success due to the collaboration of willing and committed partners, each of whom brought essential resources and expertise to assure an effective solution for meeting a critical need in Haiti. Lives will be saved and illnesses treated effectively because of the efforts of APHL, IRS and CDC. Doherty modestly explains, “We were able to come through. APHL has always come through in Haiti.”

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – July 20, 2010) – Pregnancy is a time of wonder and amazement — and for women with pre-existing diabetes, it is also a time for very extremely careful (and sometimes baffling) disease management. How do you plan for this? What risks are involved? What can you expect? The August issue of Diabetes Forecast, the consumer magazine of the American Diabetes Association, features articles about pregnancy with pre-existing diabetes to help you. With good care and planning, says Diabetes Forecast, women with either type 1 or type 2 diabetes can have safe pregnancies — and healthy babies.

Planning starts now. If you have diabetes and want to become pregnant, the first step should be visiting your doctor — or several doctors. Depending on your diabetes management, you may want to see an endocrinologist in addition to your ob-gyn for a pre-conception visit. When choosing your doctors, keep in mind that you may have appointments as often as twice a week, so try to find a physician that you are comfortable with and whose office you are comfortable getting to.

While pre-existing diabetes automatically puts your pregnancy in the high-risk category, healthy habits can lower the chance of problems for both mother and child. First and foremost, keep your blood glucose in check — in general, your A1C should be below 7 percent before you conceive. Your health care team may also want to discuss your weight, use of prenatal vitamins and other supplements, the status of any diabetes-related complications, and your current medications (such as ACE inhibitors or statins, which are not considered safe for use in pregnancy). Polycystic ovary syndrome is associated with type 2 diabetes, so for some women with diabetes, asking about fertility treatments may also be in order.

Once you become pregnant, your body’s changes can make blood glucose levels go from one extreme to the other. “I spent the entire first trimester with my face buried in the fridge,” says Kerri Sparling, 31, who has type 1 diabetes and whose daughter was born in April. “I was low all the time. It wasn’t until probably the second trimester that the insulin resistance kicked in. Everything I ate, the insulin didn’t cover it.” As your body changes through your pregnancy, so will its reactions to the elements you normally use to manage your blood glucose, so be prepared to communicate with your health care team often and make any necessary adjustments.

From pre-conception planning to integrating diabetes management into your birth plan and facing post-partum depression, having a baby can seem like an overwhelming task for women with diabetes, and yet, many women with diabetes find they have the best glucose control of their life during pregnancy. “This was so, so important to me that I was willing to do whatever to make sure she came out right,” says Sparling. “It’s so worth it.” Find more advice, explanations and insight about what to expect in the August issue of Diabetes Forecast.

This issue of Diabetes Forecast also features:

• A Birthday Challenge: Marking 40 years with 40 races for ADA’s Team Diabetes
• Drinking Calories: How you hydrate yourself makes a difference
• A Serious Subject: Dealing with erectile dysfunction

Diabetes Forecast has been America’s leading diabetes magazine for more than 60 years, offering the latest news on diabetes research and treatment to provide information, inspiration and support to people with diabetes. 

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure, and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

IRVINE, CA–(Marketwire – July 19, 2010) –  The Cystinosis Research Foundation has named three prominent researchers to its Scientific Review Board, which reviews and recommends applications for grants to study the rare and fatal metabolic disease and develop new treatments and a cure. Cystinosis afflicts about 2,000 persons, mostly children, worldwide.

Joining the CRF’s Scientific Review Board are: Drs. Stephanie Cherqui of The Scripps Research Institute, La Jolla, Calif.; Allison Eddy of the University of Washington, Seattle, Wash. and Francisco Emma of the Bambino Gesù Children’s Hospital in Rome.

Leaving the CRF’s Scientific Review Board and retiring from a historic career in metabolic disease research is Dr. Jerry Schneider, M.D., who was Professor of Pediatrics and Dean for Academic Affairs at the University of California, San Diego. He is a developer of the two breakthrough treatments for cystinosis, which he began studying in 1965.

“We are fortunate to have such pre-eminent scientists advising us on funding cystinosis research. Over the years, they have made valuable contributions to cystinosis research and are committed to finding improved treatments and a cure,” said Nancy Stack, President and co-founder of the CRF.

She added that the lifelong research on cystinosis by Dr. Schneider “has brought us to the threshold of a new treatment and a cure. He has encouraged and mentored new researchers who now, in turn, have dedicated their careers to cystinosis. Cystinosis patients and their families owe him eternal gratitude,” Stack said.

Dr. Cherqui, Ph. D., an assistant professor at The Scripps Research Institute, is credited with developing a breakthrough cell and gene therapy regimen that has improved cystinosis in mice. She is a member of the CRF Gene Therapy Consortium. Dr. Cherqui worked in Paris with a group led by Dr. Corinne Antignac that identified the cystinosis CTNS gene. Her 2002 doctoral thesis was on molecular studies of cystinosis and the generation of the mouse model for cystinosis. Dr. Cherqui is a member of the American Society of Gene and Cell Therapy. She has authored 12 publications on cystinosis, including a cover article in the October issue of the scientific journal “Blood.”

Dr. Eddy, M.D., professor of pediatrics at the University of Washington, is internationally recognized for her work on the cellular and molecular basis of kidney fibrosis and progressive kidney disease. She is the director of the Tissue and Cell Biology Research Center at Seattle Children’s Research Institute and in 2009 was elected to the Council of the International Society of Nephrology. Dr. Eddy holds the Robert O. Hickman Endowed Chair in Pediatric Nephrology at the University of Washington. She is a graduate of the McMaster University Medical School in Canada.

Dr. Emma, M.D., is head of Pediatric Nephrology at the Bambino Gesù Children’s Hospital in Rome, Italy, and president of the Italian Society of Pediatric Nephrology. Dr. Emma’s laboratory research on cystinosis has been focused on studying cell mechanisms that regulate the expression of the CTNS gene and different isoforms of the cystinosin protein. He recently began studying the therapeutic potentials of stem cells for treatment of cystinosis with the support of the CRF. Dr. Emma received his medical degree from the Catholic University of Louvain, Brussels, Belgium. He trained at Children’s Hospital, Harvard Medical School, Boston, Mass.

Cystinosis is a metabolic disease that slowly destroys every organ in the body, including the liver, kidneys, eyes, muscles, thyroid and brain. There is a medicine that prolongs the children’s lives, but there is no cure. Most cystinosis sufferers succumb to the disease or its complications by age 40.

In patients with cystinosis, the amino acid cystine accumulates in the tissue due to the inability of the body to transport cystine out of the cell. This causes development of crystals, resulting in early cell death. There is a medication but, as yet, no cure for the disease.

Twice a year the CRF announces worldwide calls to the scientific community for research proposals. Since 2003, the CRF’s Scientific Review Board has played a key advisory role for 78 research grants totaling $11.8 million to scientists studying cystinosis in North America and Europe. Currently, there are 48 CRF-funded studies underway along with 13 CRF research fellows in the United States, Canada, France, Italy, Belgium, Ireland, Germany and The Netherlands.

The CRF is the leading funding source for cystinosis research. The foundation recently approved requests totaling $988,759 for seven new grants. Every dollar raised by the CRF is committed for medical research. Administrative costs are privately underwritten.

Nancy Stack and her husband, Geoffrey, a managing director of the SARES REGIS Group, an Irvine real estate company, have a daughter, Natalie, 19, with cystinosis.

For more information about Cure Cystinosis International Registry and the Cystinosis Research Foundation of Irvine, Calif., call Zoe Solsby at (949) 223-7610 or visit www.cystinosisresearch.org.

MUNDELEIN, IL–(Marketwire – July 16, 2010) – Medline Industries, Inc., the company who produced the original Pink Glove Dance, is looking for breast cancer survivors in the San Francisco area who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating almost 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves.

When and where will it be?
Filming will take place Saturday, July 24^th at 3:00 p.m. in the big field just east of Fort Point Pier, with the Golden Gate Bridge in the background.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com/sign-up.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Details of the day, and any weather updates, will be posted on www.pinkglovedance.com.

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country called to see if they could be part of the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

ALEXANDRIA, VA–(Marketwire – July 14, 2010) –  On Wednesday, July 14, the Obama Administration joined medical professionals and leaders from the health community to announce preventive health care coverage made available under the Affordable Care Act. Under this act, new insurance plans are required to provide preventive care without cost-sharing, which will remove financial barriers for many Americans for preventive services that can help alleviate disease and reduce costs. 

The American Diabetes Association believes that while this is laudatory, relying exclusively on the United States Preventive Services Task Force (USPSTF) “A and B” recommendations, will not lead to adequate screening of patients at risk for diabetes. Blood glucose screening is one of the most essential tools for detecting diabetes and something that should be part of a basic package of benefits and services. 

Under the new rule, asymptomatic adults with sustained high blood pressure will have access to diabetes screening and adults and children will have access to obesity screening and counseling through their clinician at no cost. Ensuring that patients with other risk factors, such as a family history of diabetes or who are obese, also have access to preventive screenings at low or no cost will allow for earlier diagnosis and subsequent prevention of dangerous and costly complications. 

Through implementation of the Affordable Care Act we must ensure that patients at high risk of diabetes are screened for the disease when they see their primary care physician. Nearly 6 million of the 24 million Americans living with diabetes have not been diagnosed. There is an additional 57 million Americans with pre-diabetes, and nearly 93 percent do not know it. If left untreated, diabetes leads to costly and dangerous complications such as blindness, amputation, heart disease, and kidney disease. Relying solely on the USPSTF recommendation, which gives an “I” statement to blood glucose screening for any asymptomatic patient not experiencing high blood pressure, will continue to leave millions of Americans undiagnosed and in danger of facing otherwise avoidable health complications such as blindness, amputation, heart disease, and kidney disease.

We are supportive of the provisions that cover obesity screening and other diabetes-related prevention services. We look forward to working with the Obama Administration and Congress to ensure that people have access to diabetes screenings, as well as to the preventive services that help to manage the disease and prevent complications following diagnosis.

American Diabetes Association guidelines (below) recommend screening for individuals who meet the common risk factors for diabetes. These criteria are consistent with those used in scientific studies of diabetes prevention.

• All adults who are overweight and have additional risk factors:
  • Physical inactivity
  • First degree relative with diabetes
  • Women diagnosed with gestational diabetes or who delivered a baby weighing > 9 lb.
  • Hypertension (high blood pressure) or cholesterol abnormality
  • Other clinical conditions associated with resistance to the effects of insulin
• In the absence of the above criteria, testing should begin at age 45 years
• If results are normal, testing should be repeated at least at 3 year intervals, with consideration of more frequent testing depending on initial results and risk status.

The American Diabetes Association believes that targeted diabetes screening as outlined by the our recommendations and supported by the National Institute of Diabetes and Digestive and Kidney Diseases, and are in line with risk factors recommended by the Centers for Disease Control and Prevention must be considered a covered preventive service. Doing so will meet the dual goals of the Affordable Care Act, that is emphasizing prevention and reining in healthcare costs.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

NEW YORK, NY–(Marketwire – July 13, 2010) – Maimonides Medical Center Urologist Dr. Ridwan Shabsigh, director of the Division of Urology, created his “Ask The Doctor” medical advice talk show to help bridge the gap of men’s healthcare information in a simple-to-understand format. His online health talk show, “The Dr. Ridwan Show” delivers accurate and usable health information on common men’s health questions.

Along with an elite panel of experts, Drs. Harry Fisch, Michael Perelman and Richard Sadovsky, the group provides reliable health information to common men’s health questions. Ridwan and his medical panelists provide unique insights and advice that support the show’s tagline, “Health information you can use.” The panelists discuss a hot topic per episode in men’s health such as heart disease, prostate cancer, testosterone deficiency and erectile dysfunction.

Each episode of Dr. Ridwan’s unique online doctor consultation show concludes with helpful action tools that incite viewers to take positive actions for their health. The most helpful action tool is a men’s health calculator. This health risk calculator helps to raise awareness and motivate men to access health care services and pursue healthier lifestyles.

This men’s health calculator is not an absolute measure of risk or a substitute for professional health advice, but it helps men to assess their risk of having hypertension (high blood pressure), hyperlipidemia (high cholesterol), diabetes and/or coronary artery disease. The viewer can answer basic questions on health status, erectile dysfunction, relationships, and waist size to help determine health risk.

Other helpful tips provided on Dr. Ridwan’s doctor advice show:

• Avoid abdominal obesity to prevent heart and vascular disease risk
• Men’s health preventive ideas
• Get annual checkup and prostate screenings
• Ask for urologist referral if abnormal urinary symptoms exist
• Men should work with partners to improve health
• Review health risks and reduce these factors
• Watch for sexual problems
• Be aware of testosterone deficiency symptoms

By providing answers to medical questions online, Dr. Ridwan hopes to reduce the need for unnecessary procedures and tests. “In these times of healthcare reform, by educating my viewers, I hope to make them be more proactive in monitoring their health,” said Ridwan. “This way they won’t have to make unnecessary trips to the emergency room for something that can be taken care of in advance or prevented.”

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – July 13, 2010) – Prepararse para el verano significa sembrar
los jardines, limpiar el asador y salir a comprar trajes de baño. Los
productos del verano y las opciones para cocinar también significan que la
temporada es una oportunidad para mejorar sus hábitos alimenticios. La
Asociación Americana de la Diabetes anunció hoy sobre una herramienta en
línea de nutrición en español y en inglés que le ayudará a prepararse para
la temporada.: MiConsejerodeComida™ http://tracker.diabetes.org/es/.

MiConsejerodeComida tiene características nuevas y mejoradas que le
permitirán a las personas a mantener un registro de sus comidas diarias,
sustituir alternativas más saludables para recetas o en el plato. Las
personas con diabetes, enfermedades cardiacas, enfermedad renal, alta
presión arterial, alto colesterol y aquellas personas que quieren bajar de
peso pueden utilizar MiConsejerodeComida para encontrar información
nutricional sobre calorías, carbohidratos, sodio, grasa y colesterol.

“Hacer pequeños cambios al tiempo de la comida puede tener un impacto
positivo en su salud,” comentó Lorena Drago, RD, CDE, voluntaria de la
Asociación Americana de la Diabetes. “MiConsejerodeComida le puede enseñar
hacer alternativas saludables, crear metas y registrar lo que come. Si
pierde solamente 10 o 15 libras, usted puede ponerle alto a la diabetes al
prevenir o retrasar la diabetes tipo 2 o sus complicaciones…”

Las características nuevas incluyen:

• Versión en español – Todo el sitio web está disponible ahora en
  español. La prevalencia de la diabetes es de 2 a 4 veces más alta entre
  los hispanos/latinos.
• Regístrelo – Usted puede crear sus metas para calorías,
  carbohidratos, sodio, grasa saturada y fibra y compararlas con lo que
  actualmente está comiendo y lo que quisiera comer. Este análisis le permite
  hacer opciones más saludables para reducir el consume de sodio y grasa
  saturada o para mantener su consumo de carbohidratos consecuente en el día
  a día.

Las características actualizadas incluyen:

• Alternativa saludable – Esta característica, exclusiva a
  MiConsejerodeComida™, le permite buscar comidas más saludables. Por
  ejemplo, si busca una alternativa más saludable para la carne de res
  molida para su receta favorita de hamburguesa, le proporcionaría otras
  opciones de carne molida tales como, pavo molido o alternativas
  vegetarianas. El algoritmo, que es basado en investigaciones recientes,
  toma en cuenta 13 nutrientes diferentes para recomendar la mejor
  alternativa basándose en sus selecciones.
• Análisis de recetas – Analice sus recetas favoritas con nuestra
  función de Crear un plato. Usted puede solicitar opciones más saludables
  para los ingredientes de su receta para hacer que un viejo favorito sea un
  favorito saludable. Sus propias recetas pueden ser guardadas en su
  recetario e importadas a la herramienta de registro y los ingredientes
  pueden ser agregados a su lista de compras.
• Crear un plato – Los tamaños de las porciones han sido
  incrementadas para reunir sus preferencias al utilizar medidas simples de
  cocina.
• Navegación simple – Esto le permite buscar y comparar opciones
  de comidas con más facilidad.

“Los tamaños de las porciones en MiConsejerodeComida son basadas en 15
gramos de carbohidratos, lo cual hace que sea más fácil para las personas
con diabetes y sus cuidadores a contar carbohidratos. MiConsejerodeComida
también tiene información sobre fósforo y potasio, 2 nutrientes importantes
que se deben vigilar para las personas con enfermedad renal, comentó Lorena
Drago. “Sin importar para qué, MiConsejerodeComida puede ayudar a cualquier
persona a prepararse para el verano al enseñarle como hacer mejores
opciones de comida.”

La Asociación Americana de la Diabetes es líder en la lucha para ponerle
alto a la diabetes y sus consecuencias fatales y lucha por las personas
afectadas por esa enfermedad. La Asociación financia la investigación a fin
de prevenir, curar y controlar la diabetes; ofrece servicios para cientos
de comunidades; suministra información objetiva y verosímil; y da voz a
aquellas personas privadas de sus derechos como consecuencia de la
diabetes. La Asociación se fundó en 1940. Nuestra misión es prevenir y
curar la diabetes, así como mejorar la vida de todas las personas afectadas
por esa enfermedad. Para más información llamar al 1-800-DIABETES
(342-2383) o visitar www.portufamilia.org. Información sobre ambas fuentes
se encuentra disponible en inglés o en español.

ALEXANDRIA, VA–(Marketwire – July 13, 2010) –  Summer means gardening, grilling, and swimming at the pool. Summer’s produce and expanded cooking options also mean the season is an opportunity to improve your eating habits. The American Diabetes Association announced today a completely revised online nutrition tool in English and Spanish to help you get ready for the season: MyFoodAdvisor™ (www.diabetes.org/MyFoodAdvisor).

The award-winning MyFoodAdvisor has new and expanded features that allow people to track their daily meals, substitute healthier alternatives in recipes or on the plate, and browse recipes. People with diabetes, heart disease, kidney disease, high blood pressure, high cholesterol and those looking to lose weight can use MyFoodAdvisor to find nutrition information on calories, carbohydrates, sodium, fat and cholesterol.

“You would be surprised to see how small substitutions at meal time can make a real difference in your health,” commented Christine Tobin, CDE, President, Health Care & Education, American Diabetes Association. “MyFoodAdvisor can set you up for success by showing you healthy alternatives, tracking what you eat and helping create goals. Losing 10 or 15 pounds can help stop diabetes by preventing or delaying type 2 diabetes or diabetes complications.”

Join American Diabetes Association’s Director of Nutrition and Clinical Affairs Stephanie Dunbar, MPH, RD, and USA Today’s Medical Reporter Mary Brophy Marcus to discuss healthy eating and using the completely revised MyFoodAdvisor during a Twitter Chat on Thursday, July 15, at 2 p.m. ET, at @AmDiabetesChat and #ADA_USAT.

New features include:

• Track It – You can create your own goals for calories, carbohydrate, sodium, saturated fat and fiber and compare what you currently are eating to what you want to be eating. This analysis allows you to make healthier options to lower sodium or saturated fat intake or to keep your carbohydrate intake consistent from day to day.
• Spanish Version – The entire web site is now available in Spanish. The prevalence of diabetes is 2 to 4 times higher among Hispanics/Latinos.

Updated features include:

• Healthy Alternative – This feature, unique to MyFoodAdvisor™, allows you to search for healthier foods. For example, searching for a healthier alternative to ground beef for your favorite burger recipe would provide choices for other ground meat products like turkey or even vegetable-based meat alternatives. The algorithm, based on recent research, takes into account 13 different nutrients to recommend the best alternatives based on your selections.
• Recipe Analysis – Analyze your favorite recipes with our Create Dish functionality. You can request healthier options for all of your recipe ingredients to make your old favorite a healthier favorite. Your own recipes can be saved in your recipe box and imported into the tracking it tool, and ingredients added to a shopping list.
• Create Dish – The portion sizes have been expanded to meet your preferences for using simple cooking measurements.
• Simpler Navigation – The new version allows you to better search and compare food options.

“For people with diabetes and their caregivers, one of MyFoodAdvisor’s useful features remains that serving sizes are based on 15 grams of carbohydrate, which makes it easier to count carbs. There is also information on phosphorus and potassium, two important nutrients to watch for people with kidney disease,” commented Tobin. “But MyFoodAdvisor can help anyone looking to make smart food choices this summer.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

MUNDELEIN, IL–(Marketwire – July 12, 2010) –  Only 40 percent of infection control professionals indicated that more than three-quarters of the nurses at their facility were applying the CDC’s CAUTI prevention guidelines, and less than half reported that their facilities were conducting annual education and training on alternatives to catheterization, according to a survey conducted today. The survey of infection control professionals was conducted at a breakfast forum on prevention of catheter-associated urinary tract infections (CAUTI), sponsored by Medline Industries, Inc. in conjunction with the Association for Professionals in Infection Control and Epidemiology (APIC) Annual Scientific Meeting being held in New Orleans, LA. 

Additionally, while nearly 80 percent of attendees cited CAUTI prevention as one of their facility’s top priorities this year, almost half reported that they do not have an annual competency validation process for staff to assure that they are competent in CAUTI prevention measures and inserting Foley catheters.

“These results reaffirm the need for industry vendors to partner with healthcare providers on a comprehensive system that incorporates proper procedures and social behaviors that are easy to adopt in everyday practice,” said Lorri Downs, R.N., B.S.N., M.S., C.I.C., vice president of Infection Prevention at Medline and a board certified infection preventionist. “Reducing CAUTI rates is not just about taking precautions. We must transfer knowledge to the bedside clinician in new ways such as through interactive learning and online competency validation courses to ensure industry guidelines become the standard course of care.”

That was the experience at Arkansas Methodist Medical Center, located in Paragould, AR. The organization did not have a formal education program in CAUTI prevention prior to implementing Medline’s ERASE CAUTI program, but has seen significant results since it began using the evidence-based program three months ago.

“Since we’ve been using the ERASE CAUTI program, our facility has experienced an almost 20 percent decrease in our CAUTI rate and a more than 10 percent decrease in the number of Foley catheters placed,” said Lisa Bridges, infection preventionist at Arkansas Methodist Medical Center. “I believe the decreases will be even more in the coming months. We are still in the process of educating our staff on following the guidelines. Having the checklist on the outer packaging helps us to make sure that catheterization is an appropriate option for the patient.”

Medline is highlighting evidence-based CAUTI prevention practices and products at this year’s APIC Congress (booth #1907). During the three-day exhibition, Medline is demonstrating its ERASE CAUTI program, a revolutionary new approach to managing catheters and reducing CAUTI. Based on the same criteria the CDC used in developing their new CAUTI prevention guidelines, the ground-breaking ERASE CAUTI program features a reengineered one-layered catheter tray coupled with an evidence-based clinical education program.

As part of its presentation, the Medline clinical team is conducting a series of live, multimedia overviews of its cutting edge competency validation tools for assessing and sustaining staff results. The interactive competency programs are available to staff anytime via Medline University, Medline’s online education resource, and can be easily incorporated into the annual skills competency program for a facility’s nursing staff.

CAUTI is one of the most common healthcare-associated infections, not only comprising 40 percent of all institutionally acquired infections, but also eight percent of infections in the home care setting. Studies show that one in four patients receives an indwelling urinary catheter at some point during their hospital stay and up to 50 percent of these catheters are placed unnecessarily.

Additional information on the ERASE CAUTI program is available on Medline’s website at www.medline.com/erase.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

SILVER SPRING, MD–(Marketwire – July 12, 2010) –  The Association of Public Health Laboratories (APHL) has received an award for $16.3 million from the Centers for Disease Control and Prevention (CDC) to enhance the work of public health laboratories in the US and abroad. The award continues an APHL-CDC collaboration of over 20 years in support of governmental health laboratories.

Funded as a five-year cooperative agreement, the award will assist APHL to promote quality public health laboratory practice, strengthen the public health laboratory system and develop a well-trained workforce. 

“APHL is committed to improving health outcomes by strengthening the capacity of public health laboratories both nationally and globally,” said Dr. Patrick Luedtke, director of the Unified State Laboratories in Utah and APHL president. “Public health laboratories protect us against diseases, environmental hazards, natural disasters and other health threats. A stronger lab system means healthier people.”

APHL is a leader in development and implementation of public health laboratory practice, systems, policy and training. Members serve as laboratory first responders, protecting the public from diseases and environmental health hazards. 

The Association of Public Health Laboratories is a national non-profit located in Silver Spring, MD, that is dedicated to working with members to strengthen governmental laboratories with a public health mandate. By promoting effective programs and public policy, APHL strives to provide public health laboratories with the resources and infrastructure needed to protect the health of US residents and to prevent and control disease globally.

Click here to see all recent news from this company

LONG ISLAND, NY–(Marketwire – July 9, 2010) –  SciMeDent Health Corp. f/k/a Trend Exploration, Inc. (“TRDX” or the “Company”) (PINKSHEETS: TRDX) today announces plans to appoint Dr. Bahige Baroudy of Genesis Biopharma to the equivalent role of Chief Science Officer at TRDX for the continued development of a potential cure for diabetic neuropathy.

Dr. Bahige Baroudy has multi-disciplinary expertise in basic research, infectious disease drug discovery and virology. Prior to joining Genesis Biopharma, Dr. Baroudy was a Group Director at Schering-Plough where he spearheaded the development of CCR5 antagonists that are currently in clinical trials as HIV entry inhibitors and earned a place on “The Scientific American 50” list as the top Research Leader in 2003 in this category. He was also the Director, Division of Molecular Virology at the James N. Gamble Institute of Medical Research, where he established research programs in viral hepatitis and liver diseases, HIV/AIDS and vaccinia virus expression and pathogenesis. Dr. Baroudy has also worked at the NIH in several disciplines.

Dr. Baroudy stated: “We are pleased that we have received the approval of Health Canada to proceed to Phase 1 clinical studies.”

Dr. Jan Stahl, CEO of TRDX, commented: “We look forward to the work Dr. Baroudy will execute in bringing this potential cure to market.”

About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell of every living thing on Earth. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called “amide bonds”).

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements
A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company’s business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

SCOTTSDALE, AZ–(Marketwire – July 6, 2010) –  EmpowHER is offering free access to world-class health information as well as a community of experts and advocates to the millions of women interested in current research on cord blood and stem cells. These resources are offered in support of the Cord Blood Awareness Month, which occurs in July and is sponsored by the American Hospital Association.

Cord blood is the blood located inside the umbilical cord after the cord has been cut. It is rich with stem cells, which have the ability to regenerate and form cells that create all other tissues, organs, and systems in the human body. The unique and special characteristics of cord blood cells provide the possibility of healing some cancers or inherited diseases. Also, according to the American Pregnancy Association, cord blood stem cells are oftentimes rejected less by the body as compared to healthy adult bone marrow stem cells. If a parent elects to do so, cord blood can be stored at the time of an infant’s delivery for medical use in the future. Some experts question the effectiveness of storing cord blood, however, as it may contain the same cells that caused a disease or medical condition in the child, the National Institutes of Health reports.

According to research published in the Journal of Reproductive Medicine, 3 out of every 4 pregnant women consider themselves only “minimally informed” about this issue.

For women wanting to learn more about this issue, EmpowHER offers invaluable content on its site where women can find topical medical articles and guides to additional online resources on cord blood and stem cell research and therapies.

To access cord blood content on EmpowHER, please click the links below:
Cord Blood Resource Page
Thinking About Cord Blood Banking?
Cord Blood Donation
Cord Blood Banking – The Medicine of the Future?
Growing New Organs From Cord Blood – Why Transplants May Not Be Needed In Future
Can Obama Cure Cancer With Stem Cell Research?

“More women need to understand what cord blood donation really entails and what the reasons behind it are,” says Michelle King Robson, EmpowHER’s Founder, Chairperson and CEO. “This way, pregnant women considering cord blood donation can make more informed decisions when offered this option at childbirth.”

About EmpowHER
EmpowHER is an award-winning health media company for women. The Company’s website provides visitors access to one of the largest women’s health and wellness content libraries on the web, as well as the largest online community of women discussing their health and wellness issues. EmpowHER promotes a “24 Hour Promise” to its visitors, who can come to the site, ask any health question and receive a response within 24 hours. Health care marketers rely on EmpowHER for reaching the most influential health and wellness buying audience on the Internet — women. Millions of women visit EmpowHER.com every year, making it one of the largest and fastest-growing resources dedicated exclusively to women’s health and wellness. For more, visit www.empowher.com.

Click here to see all recent news from this company

ALBUQUERQUE, NM–(Marketwire – July 1, 2010) –  The nation’s first scientific study on the effects of wood smoke in smokers shows that wood smoke is associated with chronic obstructive pulmonary disease (COPD), and has identified a link that increases the risk for reduced lung function in cigarette smokers. That exposure to wood smoke causes COPD was previously found to be common in women in developing countries, but has not been recognized as being a hazard at concentrations generally found in developed countries. 

The objective was to evaluate the risk of wood smoke for COPD in a population of smokers in the United States, and whether non-hereditary changes of DNA that were detected in sputum samples of these patients were correlated to the disease of COPD as shown by the destruction of lung function. The association between wood smoke and reduced lung function was stronger among current cigarette smokers, non-Hispanic whites and men.

Lead investigators at Lovelace Respiratory Research Institute (LRRI) in New Mexico, the only dedicated respiratory research center in the US, in collaboration with the University of New Mexico School of Medicine and the University of Colorado at Denver, conducted the study which was financed by the appropriation from the Tobacco Settlement Fund, and from the National Institutes of Health (NIH). The findings were recently published in the American Journal of Respiratory Critical Care Medicine, a publication by the American Thoracic Society.

Yohannes Tesfaigzi, Ph.D., Senior Scientist at LRRI based in ABQ, NM and lead investigator, said, “The findings are significant and timely because it shows that there are many factors that reduce lung function in the world today.” Tesfaigzi continued, “Our findings suggest that smokers of cigarettes who are exposed to wood smoke increase their risk of having reduced lung function.”

For the research, a cross sectional study of 1,827 subjects were drawn from the Lovelace Smokers’ Cohort, a predominantly female cohort of smokers that is unique with its high percentage of Mexican Hispanic participants. The wood smoke exposure was self-reported. The research included measuring air entering and leaving the lungs, airflow obstruction and chronic bronchitis. Also explored were modification of wood smoke exposure with current cigarette smokers, ethnicity, sex, and the relationship with lung cancer-related genes on COPD. 

Robert W. Rubin, Ph.D., CEO of Lovelace Respiratory Research Institute, said, “Many people use wood smoke as a major heating source and also smoke cigarettes, and this research proves that it can be a very unhealthy combination.” Rubin continued, “With the legitimate concern to find alternative energy and heating methods in the world, we need more research of this kind to make certain that we do not add to the many factors in the air we breathe that will contribute to the destruction of lung function.” 

About Lovelace Respiratory Research Institute

The Lovelace Respiratory Research Institute (LRRI) is a private, biomedical research organization dedicated to improving public health through research on the prevention, treatment and cure of respiratory disease. LRRI is committed to curing respiratory diseases through research aimed at understanding their causes and biological mechanisms; assessing and eliminating exposures to respiratory health hazards; and developing improved therapeutics, vaccines, and diagnostics. LRRI is based in Albuquerque, New Mexico, employs 1100 people, and is a $125 million company. www.lrri.org

Click here to see all recent news from this company

ORLANDO, FL–(Marketwire – June 29, 2010) –  Five-year results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study confirm that neither more intensive lowering of blood glucose (sugar) levels, more intensive lowering of blood pressure, nor treatment of blood lipids with a fibrate and a statin drug reduce cardiovascular risk in people with established type 2 diabetes who are at severely high risk for cardiovascular events. However, the study did find improvements to microvascular conditions, such as progression of diabetic eye disease (retinopathy), visual acuity, and renal and nerve function. The landmark study is sponsored by the federal government through the National Institutes of Health (NIH).

Speaking at the American Diabetes Association’s 70th Scientific Sessions^®, the ACCORD Study Group cautioned that any potential benefits must be weighed against the increased risk of mortality and episodes of seriously low blood glucose that were seen to accompany intensive lowering of blood glucose levels — which in ACCORD was focused on achieving normal A1C levels in the study population. They emphasized that both the positive and negative results of the study apply only to this population of middle-aged or older people with type 2 diabetes for an average of 10 years, who also had a history of cardiovascular disease (CVD) or at least two risk factors for CVD.

“These results underscore the importance of patient-centered care that stresses individual treatment choices made in consultation with a physician,” said Denise Simons-Morton, MD, Ph.D, Director of the Division for the Application of Research Discoveries at the NIH’s National Heart, Lung and Blood Institute (NHLBI), the primary sponsor of the study. “Within this group, it’s important for patients and doctors to decide the highest priority for the patient,” she said. “Is improved eye health worth a higher risk of death and low blood sugar episodes? That’s a question only a fully informed patient can answer.”

The ACCORD researchers set out to investigate whether cardiovascular risk in people with type 2 diabetes could be reduced using one of the following strategies, each compared with standard treatment: intensive lowering of blood glucose to near-normal levels (target A1C less than 6%), intensive lowering of blood pressure to near-normal levels, or treatment of blood lipids with a combination of fibrate and statin drugs. It also looked at how each of these treatments would affect other outcomes such as mortality and microvascular outcomes (e.g., eye, kidney and nerve complications). 

NHLBI prematurely halted the intensive blood-glucose lowering strategy after 3.5 years, in February 2008, due to safety concerns caused by an unexpected higher incidence of death in the intensive glucose lowering treatment group compared with the standard treatment group. Patients in the intensive treatment arm of the study were transitioned into the standard treatment arm for the remainder of the trial’s five years, which has now concluded.

Intensively Lowering Blood Glucose: Increased Mortality and No Cardio Benefit, But Possible Benefits to Eyes, Kidneys and Nerves

Results of intensive glucose lowering on microvascular outcomes were published today in the Lancet and presented at a symposium at the American Diabetes Association’s 70^th Scientific Sessions in Orlando.

The study examined patients who underwent intensive glucose-lowering treatment for 3.5 years (increased medication aimed at lowering A1C levels to less than 6 percent) and were then given standard treatments (aimed at achieving A1C levels of 7.0-7.9%) for the remaining 1.5 years, compared with standard treatment for the duration of the study. The intensively treated patients did not see a reduced incidence of cardiovascular disease.

In addition, the groups did not differ in overall measures of microvascular health, for example, in the progression rates to kidney failure, major vision loss, or advanced peripheral neuropathy, a common nerve problem in diabetes that usually begins as tingling or numbness in the feet. However, there were some microvascular improvements noted, such as a reduced incidence of albuminuria (protein in the urine, a marker of kidney disease) in the intensive group, compared to those receiving standard treatment, along with fewer cataract extractions during the study period. Visual acuity (sharpness of vision) and nerve function scores were also better for the intensive group than for the standard-treatment group, suggesting that intensive lowering of blood glucose may also help prevent eye and nerve damage.

“Patients who develop macroalbuminuria are prone to renal failure and cardiovascular events,” said Faramarz Ismail-Beigi, MD, Ph.D, of Case Western Reserve University and the lead researcher on this portion of the study. “Less protein in the urine is a very good sign.”

Though the visual acuity tests were somewhat subjective, Ismail-Beigi said, they could indicate that intensive glucose lowering helps to prevent eye damage.

Intensively Lowering Blood Glucose, Treating Lipids: Slows Retinopathy Progression

That finding is further supported by a substudy of ACCORD chaired by Emily Chew, MD, chief of the Clinical Trials Branch of the Division of Epidemiology and Clinical Applications at the NIH’s National Eye Institute (NEI). Results of the study were published online in the New England Journal of Medicine today. Chew and her colleagues investigated whether each treatment arm of the ACCORD trial — blood glucose, blood pressure, and blood lipids — would reduce the progression of diabetic eye disease (or retinopathy) in a subset of about 3,000 ACCORD study participants, compared to that treatment’s standard approach. Disease progression was identified through retinal photographs that indicated blood vessel changes or by the need for laser or vitrectomy surgery to treat abnormal blood vessels.

The study found that people in the intensive blood glucose lowering arm, as well as those who received a combination of a fibrate and a statin for blood lipids, experienced slower progression in diabetic retinopathy than those in each standard treatment arm. Those who were in the intensive blood pressure lowering arm did not see a reduction in eye disease progression when compared to people receiving standard blood pressure control.

Compared with standard blood glucose control, intensive control decreased the progression of diabetic retinopathy by about one-third, from 10.4 percent to 7.3 percent, over four years. Participants in the intensive control group had a median blood glucose level of 6.4 percent hemoglobin A1C — a level close to values in people without diabetes. The standard blood glucose control group maintained a median level of 7.5 percent.

In addition, compared with simvastatin treatment alone, combination lipid therapy with fenofibrate plus simvastatin also reduced disease progression by about one-third, from 10.2 percent to 6.5 percent, over four years. No prior clinical trial has shown that the combination of fenofibrate and simvastatin reduces diabetic eye disease progression.

Contrary to predictions, there was no difference in diabetic retinopathy progression among participants treated to an intensive systolic blood pressure (the top number in a blood pressure reading) target of less than 120 mm Hg, compared with those treated to a standard target of less than 140 mm Hg.

“The results of the ACCORD Eye Study indicate that intensive blood sugar control and combination fibrate plus statin treatment of lipids independently reduce diabetic retinopathy progression,” Chew said. “However, patients and their doctors should work together to develop an individual treatment plan, taking into account the potential risks of intensive glucose treatment.”

Combination Lipid Treatment: No Cardio Benefits Overall, But Subgroup May See Reduced Risk

Combination lipid therapy with a statin plus a fibrate did not help lower cardiovascular risks overall, but the results did suggest that a subgroup of the study — those with high triglycerides and low HDL (the so-called “good” cholesterol) — may benefit by such treatment.

In this subpopulation of the investigation, which included about 15 percent of the 5,518 people studied in the ACCORD Lipid Trial, those who had triglyceride levels of more than 200 and HDL levels below 34 saw a reduced incidence of cardiovascular events of 30 percent. These findings are supported by similar findings of subgroup populations in several large previously published clinical studies.

“If it were an isolated finding in our study I’d be less enthusiastic,” said Henry Ginsberg, MD, Irving Professor of Medicine and Director of the Irving Institute for Clinical and Translational Research at Columbia University. “But this finding is in line with subgroup analyses in several other trials.”

A second subgroup analysis of this arm of the study found that women and men respond differently to combination lipid therapy, Ginsberg said. Though overall the study found no cardiovascular benefits for the study population, when broken down by gender, the results showed men experienced a 20 percent reduction in cardiovascular events, while women experienced a 38 percent increase in cardiovascular events.

However, when examined for statistical significance, “the data for men showed a strong indication that they benefitted, while the data for women were not as conclusive,” Ginsberg said. “This raises possibilities that need to be further examined.”

These results were published in the April 29, 2010, issue of the New England Journal of Medicine.

Intensively Lowering Blood Pressure: No Cardio Benefits, But Suggested Reduction in Stroke

Results from the intensive blood pressure control arm of the study were also published in April in the New England Journal of Medicine. In this treatment arm, participants lowered blood pressure levels to “normal” levels of less than 120 mm Hg, to see if doing so would reduce major cardiovascular events, compared with standard treatment of levels less than 140 mm Hg. No significant reduction in overall CVD events was found.

The study did find a significant (41 percent) reduction in stroke, which was consistent with other BP-lowering clinical trials. However, because this was not the primary focus of the study, and because the overall rate of stroke was low, the researchers are hesitant to recommend a strategy of lowering blood pressure to this degree without further study.

“Older patients with known cardiovascular disease, higher blood pressure to begin with, and African Americans may benefit from such a treatment plan,” said William Cushman, MD, of the Memphis Veterans Affairs Medical Center, “but we’re going to have to do further analyses.”

The NHLBI is the primary sponsor of ACCORD, with additional funding and scientific expertise contributed by the National Institute of Diabetes and Digestive and Kidney Diseases. Other components of the NIH — including the National Institute of Aging — as well as the Centers for Disease Control and Prevention, support substudies. The following companies provided study medications, equipment, or supplies: Abbott Laboratories, Amylin Pharmaceutical, AstraZeneca Pharmaceuticals LP, Bayer HealthCare LLC, Closer Healthcare Inc., GlaxoSmithKline Pharmaceuticals, King Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceuticals, Inc., Novo Nordisk, Inc., Omron Healthcare, Inc., Sanofi-Aventis U.S., and Takeda Pharmaceuticals, Inc.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Symposium, June 29, 10:15 a.m.

id=”nav_links”>